News ReleasesProtox appoints Vice President, Business Development Wednesday, July 13, 2005 - Vancouver, British Columbia - Protox Therapeutics Inc. announced today that it has appointed Kevin McDuffie as Vice President, Business Development. Mr. McDuffie has over nineteen years of senior business development experience in the life sciences field. Most recently as Senior Manager of Business Development at Inex Pharmaceuticals Corporation, he was responsible for establishing collaboration agreements, leading partnership negotiations and seeking potential business relationships worldwide. Prior to Inex Mr. McDuffie managed the licensing, sales and marketing, new product introductions, and financing of a proteomics startup company, Kinexus Bioinformatics Corporation. He has negotiated several option and license agreements with pharmaceutical industry partners during his five years tenure at University Technologies International, the commercial arm of the University of Calgary. Mr. McDuffie offers extensive experience in identifying, assessing, patenting and marketing intellectual property with commercial potential. He holds a BSc. (Honours) in Biochemistry from the University of Saskatchewan and is a member of the Licensing Executives Society. He is also an active member of the Alberta Heritage Foundation Technology Commercialization Committee and Canadian Institutes Health Research Commercialization Management Grants Committee. "During the next phase of our strategic growth we are exploring a number of opportunistic licensing and partnering initiatives to accelerate expansion of our product portfolio", said Dr. Fahar Merchant, President & CEO of the Company. "Kevin brings a wealth of experience in business development and licensing from both industry and the academic sector. He is ideally suited to the needs of Protox at this time as we seek to maximize the commercial potential of our technology platform." ABOUT PROTOX: Protox Therapeutics Inc. is developing novel therapeutics for the treatment of cancer and other indications by engineering the naturally occurring bacterial toxin Aerolysin, which kills cells by forming pores in them. The Company believes that its engineering approach will produce targeted therapeutics that may have greater efficacy and fewer side effects than existing treatments. For more information, contact: |
2006 Protox Therapeutics Inc. All Rights Reserved. Legal Disclaimer. |